At 4.4% CAGR, North America Microelectrode Array In Vitro Market is Projected to be Worth US$ 11.94 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the North America microelectrode array in vitro market was valued at US$ 8.44 million in 2023 and is expected to reach US$ 11.94 million by 2031, registering a CAGR of 4.4% from 2023 to 2031. Integration of microelectrode array technologies with organ-on-a-chip and microelectrode arrays with advanced features are among the critical factors attributed to drive the North America microelectrode array in vitro market growth.

Organ-on-a-chip systems are designed to replicate the physiological conditions of human organs using microfluidics and engineered tissues. When combined with microelectrode array technology, these systems can monitor electrical activity in real-time, providing insights into the functional responses of the organ models. For instance, a "heart-on-a-chip" that integrates a microelectrode array can offer data on cardiac electrophysiology, enabling researchers to evaluate the ways different compounds impact heart rhythm and contractility. This information is essential for understanding drug-induced cardiotoxicity, which poses a significant concern in pharmaceutical development. For instance, in September 2022, NETRI, a neuro-organs-on-chip start-up, partnered with Axion BioSystems to create microfluidic devices with high-throughput microelectrode arrays. This advanced technology will allow neuroscientists to noninvasively measure the electrical activity of neural cells in complex in vitro models, accelerating therapeutic discovery. The microelectrode array is crucial to the center's organ-on-chip research, which seeks to improve biological models while reducing animal testing. The research is focused on brain-on-a-chip technology for studying neurodegenerative diseases, heart-on-a-chip technology, and blood-brain barrier modeling. Therefore, the integration of microelectrode array technologies with organ-on-a-chip devices is expected to bring new trends in the market growth in the coming years.

On the contrary, the high development costs of microelectrode arrays hamper the growth of North America microelectrode array in vitro market.

Based on product, the North America microelectrode array in vitro market is divided into classical MEA, multiwell-MEA, and CMOS-MEA. The multiwell-MEA segment held 68.0% market share in 2023, amassing US$ 5,740.35 thousand. It is projected to garner US$ 8,204.52 thousand by 2031 to register 4.6% CAGR during 2023-2031.

In terms of application, the North America microelectrode array in vitro market is segmented into cardiomyocytes, nerve, and others. The cardiomyocytes segment held 45.0% share of North America microelectrode array in vitro market in 2023, amassing US$ 3,796.93 thousand. It is anticipated to garner US$ 5,496.11 thousand by 2031 to expand at 4.7% CAGR during 2023-2031.

Based on country, the North America microelectrode array in vitro market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 90.6% share North America microelectrode array in vitro market in 2023. It was assessed at US$ 7,642.29 thousand in 2023 and is likely to hit US$ 10,855.13 thousand by 2031, registering a CAGR of 4.5% during 2023-2031.

Key players operating in the microelectrode array in vitro market are Tucker Davis Technologies, SCREEN Holdings Co., Ltd.; Plexon Inc.; MaxWell Biosystems AG, Harvard Bioscience Inc.; Axion BioSystems Inc, 3Brain AG, NeuroNexus Technologies Inc.; MicroElectrodeDevices, Blackrock Microsystems, Inc.; NMI Technologietransfer GmbH, and BMSEED, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com